Concord Healthcare Group Co., Ltd. Class H
HHKEX:24530.65
HKD
0.00
(0.00%)
ISIN
CNE100006BL7
Return %
Stock
S&P 500
1Y
-76.96
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Semi-annual Revenue
CNY
•
in mil. unless spec.Semi-annual Earnings Per Share
CNY
•
in mil. unless spec.Semi-annual Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Jianyu Yang
- Full Time Employees
- 592
- Sector
- Health services
- Industry
- Hospital/Nursing management
- Address
- East Tower, Hanwei Building Beijing BE China 100013
- IPO Date
- Jan 9, 2024
- Website
- concordmedical.com
- Similar Companies
- Business
- Concord Medical Services Holdings Limited (Ticker: 2453.HK) is a China-based company primarily engaged in the provision of radiotherapy services and operation of cancer hospitals. The company’s core offerings include installation, operation, and management of radiotherapy equipment; provision of outpatient and inpatient radiotherapy treatment services; sale and leasing of medical equipment; medical technology development; and provision of medical technology consultation services. Concord Medical operates through various cancer treatment centers across China, focusing on delivering specialized radiotherapy services to cancer patients. Established in 2005, the company is headquartered in Beijing, China. In recent years, Concord Medical has expanded its business through strategic partnerships and acquisitions to enhance its radiotherapy service capabilities and geographic reach. It has launched new service offerings by incorporating advanced radiotherapy technology and digital healthcare solutions to improve treatment efficacy and patient management. The company has also actively pursued growth in cancer hospital operations and has strengthened its presence in major Chinese cities through network expansion. These strategic moves align with Concord Medical’s goal to become a leading integrated radiotherapy service provider in China’s oncology healthcare sector. Operating primarily within the healthcare and pharmaceutical industry segments, Concord Medical serves hospitals, clinics, and individual cancer patients as its primary customer base. Its business model centers on integrating advanced cancer treatment technologies with comprehensive clinical services including diagnostics, radiotherapy, and aftercare. Through its subsidiaries and affiliated entities, Concord Medical maintains a strong operational footprint in key regions across China, supporting oncology care infrastructure growth aligned with evolving market demands.